BACKGROUND: Mothers of children who have ataxia telangiectasia have been reported to be at increased risk for development of breast carcinoma. To test whether sequence variants in the ataxia telangiectasia, mutated, gene (ATM) are associated with breast carcinoma, the authors compared the frequency of ATM cDNA sequence changes in patients with breast carcinoma with the corresponding frequency in control patients. METHODS: The authors sequenced ATM cDNA from 91 patients with breast carcinoma and compared the frequencies of sequence changes in these patients with the corresponding frequencies in a control sample of 940 individuals with no history of malignant disease. RESULTS: Thirty-five patients with breast carcinoma had one or more single-base changes in ATM. Three genetic variants were found in at least two patients. These variants resulted in Asp1853Asn, Pro1054Arg, or Ser49Cys amino acid substitutions in the ATM protein. The Ser49Cys variant was more common in patients with breast carcinoma than in the control patients, with respective frequencies of 6.7% (5 of 75 patients) and 1.3% (12 of 940 patients; P=0.006; Fisher two-sided exact test). The subgroup of patients with bilateral breast carcinoma had a Ser49Cys frequency of 11.8% (2 of 17 patients), which again was significantly different from what was observed in the control group (P=0.024; Fisher two-sided exact test). The allele frequencies of the other two variants were not different between case patients and control patients. CONCLUSIONS: Patients with breast carcinoma, particularly those with bilateral disease, were more likely to have a variant in the ATM gene that resulted in a Ser49Cys substitution in the gene product. Additional studies are needed to evaluate the potential functional consequences of the Ser49Cys substitution and confirm the relevance of this variant in the development of breast carcinoma. Copyright 2004 American Cancer Society.
BACKGROUND: Mothers of children who have ataxia telangiectasia have been reported to be at increased risk for development of breast carcinoma. To test whether sequence variants in the ataxia telangiectasia, mutated, gene (ATM) are associated with breast carcinoma, the authors compared the frequency of ATM cDNA sequence changes in patients with breast carcinoma with the corresponding frequency in control patients. METHODS: The authors sequenced ATM cDNA from 91 patients with breast carcinoma and compared the frequencies of sequence changes in these patients with the corresponding frequencies in a control sample of 940 individuals with no history of malignant disease. RESULTS: Thirty-five patients with breast carcinoma had one or more single-base changes in ATM. Three genetic variants were found in at least two patients. These variants resulted in Asp1853Asn, Pro1054Arg, or Ser49Cys amino acid substitutions in the ATM protein. The Ser49Cys variant was more common in patients with breast carcinoma than in the control patients, with respective frequencies of 6.7% (5 of 75 patients) and 1.3% (12 of 940 patients; P=0.006; Fisher two-sided exact test). The subgroup of patients with bilateral breast carcinoma had a Ser49Cys frequency of 11.8% (2 of 17 patients), which again was significantly different from what was observed in the control group (P=0.024; Fisher two-sided exact test). The allele frequencies of the other two variants were not different between case patients and control patients. CONCLUSIONS:Patients with breast carcinoma, particularly those with bilateral disease, were more likely to have a variant in the ATM gene that resulted in a Ser49Cys substitution in the gene product. Additional studies are needed to evaluate the potential functional consequences of the Ser49Cys substitution and confirm the relevance of this variant in the development of breast carcinoma. Copyright 2004 American Cancer Society.
Authors: Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond Journal: Cold Spring Harb Perspect Biol Date: 2009-12-09 Impact factor: 10.005
Authors: Robert J Livingston; Andrew von Niederhausern; Anil G Jegga; Dana C Crawford; Christopher S Carlson; Mark J Rieder; Sivakumar Gowrisankar; Bruce J Aronow; Robert B Weiss; Deborah A Nickerson Journal: Genome Res Date: 2004-09-13 Impact factor: 9.043
Authors: Li Xu; Elaine Cristina Morari; Qingyi Wei; Erich M Sturgis; Laura S Ward Journal: J Clin Endocrinol Metab Date: 2012-03-21 Impact factor: 5.958
Authors: Michael Story; Liang-hao Ding; William A Brock; K Kian Ang; Ghazi Alsbeih; John Minna; Seongmi Park; Amit Das Journal: Health Phys Date: 2012-11 Impact factor: 1.316
Authors: Denise L Stredrick; Montserrat Garcia-Closas; Marbin A Pineda; Parveen Bhatti; Bruce H Alexander; Michele M Doody; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Stephen J Chanock; Jeffery P Struewing; Alice J Sigurdson Journal: Hum Mutat Date: 2006-06 Impact factor: 4.878
Authors: Anna von Wachenfeldt; Annika Lindblom; Henrik Grönberg; Zakaria Einbeigi; Richard Rosenquist; Camilla Gardman; Lennart Iselius Journal: Hered Cancer Clin Pract Date: 2007-03-15 Impact factor: 2.857
Authors: Sean V Tavtigian; Peter J Oefner; Davit Babikyan; Anne Hartmann; Sue Healey; Florence Le Calvez-Kelm; Fabienne Lesueur; Graham B Byrnes; Shu-Chun Chuang; Nathalie Forey; Corinna Feuchtinger; Lydie Gioia; Janet Hall; Mia Hashibe; Barbara Herte; Sandrine McKay-Chopin; Alun Thomas; Maxime P Vallée; Catherine Voegele; Penelope M Webb; David C Whiteman; Suleeporn Sangrajrang; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Georgia Chenevix-Trench Journal: Am J Hum Genet Date: 2009-09-24 Impact factor: 11.025
Authors: Tú Nguyen-Dumont; Florence Le Calvez-Kelm; Nathalie Forey; Sandrine McKay-Chopin; Sonia Garritano; Lydie Gioia-Patricola; Deepika De Silva; Ron Weigel; Suleeporn Sangrajrang; Fabienne Lesueur; Sean V Tavtigian Journal: Hum Mutat Date: 2009-06 Impact factor: 4.878